Core Insights - Inspire Medical Systems, Inc. is a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea [1][3] - The company will present at two major healthcare conferences on September 4, 2024, including the Morgan Stanley 22nd Annual Global Healthcare Conference and the Wells Fargo 2024 Healthcare Conference [1][2] Presentation Details - Inspire's presentation at the Morgan Stanley conference is scheduled for 7:00 a.m. Eastern Time, with a live webcast available [2] - The presentation at the Wells Fargo conference is set for 3:00 p.m. Eastern Time, also with a live webcast [2] - Webcast replays will be accessible for two weeks post-presentation on Inspire's Investor website [2] Company Overview - Inspire's proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3] - The company focuses on the development and commercialization of innovative solutions in the medical technology sector [3]

Core Viewpoint - Inspire Medical Systems (INSP) shows potential as a strong investment opportunity due to significant revisions in earnings estimates, indicating an improving earnings outlook [1][2] Current-Quarter Estimate Revisions - The earnings estimate for the current quarter is $0.07 per share, reflecting a year-over-year increase of +124.14% [4] - In the last 30 days, five estimates have been revised upward while two have been revised downward, leading to a Zacks Consensus Estimate increase of 612.5% [4] Current-Year Estimate Revisions - The expected earnings for the full year are $0.63 per share, representing a +187.5% change from the previous year [5] - Over the past month, seven estimates have been revised upward with no negative revisions, resulting in a consensus estimate increase of 381.02% [5] Favorable Zacks Rank - The positive estimate revisions have earned Inspire a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance [6] - Research indicates that stocks with Zacks Rank 1 and 2 significantly outperform the S&P 500 [6] Bottom Line - The stock has gained 38.4% over the past four weeks, driven by solid estimate revisions, suggesting that it may be a good addition to investment portfolios [7]

Inspire Medical Systems, Inc. (INSP) reported earnings per share of 32 cents for the second quarter of 2024 against the Zacks Consensus Estimate of a loss of 14 cents per share. In the year-ago period, the company had incurred a loss of 41 cents per share. Revenues in Detail Inspire Medical registered revenues of $195.9 million in the second quarter, up 29.8% year over year. The figure beat the Zacks Consensus Estimate by 3.7%. Segment Details Inspire Medical's operations consist of two geographic regions — ...

Financial Data and Key Metrics Changes - The company generated revenue of $195.9 million in Q2 2024, a 30% increase compared to Q2 2023 [5][17] - U.S. revenue totaled $187.8 million, also a 30% increase year-over-year [5][19] - Net income for Q2 was $9.8 million, compared to a net loss of $12 million in the prior year, resulting in net income per share of $0.32 [6][19] - The company raised its full-year revenue guidance to $788 million to $798 million, representing 26% to 28% growth over 2023 [6][20] Business Line Data and Key Metrics Changes - Revenue outside the U.S. increased by 27% to $8.1 million, with notable growth in Germany, Switzerland, the Netherlands, and Belgium [6][17] - The gross margin in Q2 was 84.8%, up from 83.9% in the prior year, driven by increased sales volumes and manufacturing efficiencies [17] Market Data and Key Metrics Changes - The company expanded its U.S. presence with 81 new implanted centers and 12 new sales territories, bringing the total to 1,316 active U.S. centers and 310 sales territories [5][6] - The proposed 2025 National Medicare outpatient payment rates indicate a 2% increase, which is favorable for the company [11] Company Strategy and Development Direction - The company is focused on operational readiness for the Inspire V neurostimulation system, with a soft launch planned for May 2024 and a full launch in 2025 [9][32] - The company aims to improve patient experience through initiatives like digital scheduling, which has increased appointment scheduling success by 60% [13] - The company is also enhancing its market access through the PREDICTOR study, which aims to simplify the process for patients with lower BMI [10][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum going forward, citing resolved prior authorization challenges and strong patient demand [23] - The company anticipates continued growth driven by the adoption of Inspire therapy and the introduction of Inspire V [63] - Management highlighted the importance of GLP-1 therapies in complementing Inspire therapy, with over 1,500 patients receiving both therapies in the past two years [41][42] Other Important Information - The company announced a $150 million share repurchase authorization, marking the first in its history [15][20] - The company is actively working with payers to improve patient access and streamline reimbursement processes [49] Q&A Session Summary Question: Insights on the recent quarter's performance and future expectations - Management clarified that the strong Q2 performance was not merely a catch-up from Q1 but a reflection of improved operational momentum and patient demand [23] Question: Profitability and cost savings - Management indicated that improved productivity and targeted investments in digital advertising contributed to profitability, with expectations for continued operating leverage [25] Question: U.S. utilization and seasonal trends - Management acknowledged historical seasonality but expressed confidence in sequential and year-over-year utilization growth moving forward [28] Question: Inspire V rollout details - The company confirmed a soft launch for Inspire V in select centers, with a full launch expected in 2025, emphasizing the importance of operational readiness [32] Question: Impact of GLP-1 therapies on patient qualification - Management noted significant evidence of patients on GLP-1 therapies benefiting from Inspire therapy, with ongoing efforts to communicate this to physicians [41][42] Question: Surgeon capacity and operational efficiencies - Management discussed initiatives to improve surgeon capacity, including the use of advanced practice providers to streamline patient care processes [45]

For the quarter ended June 2024, Inspire Medical Systems (INSP) reported revenue of $195.89 million, up 29.7% over the same period last year. EPS came in at $0.32, compared to -$0.41 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $195.9 million, representing a surprise of -0.01%. The company delivered an EPS surprise of +328.57%, with the consensus EPS estimate being -$0.14. While investors scrutinize revenue and earnings changes year-over-year and how they compare ...

Inspire Medical Systems (INSP) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 328.57%. A quarter ago, it was expected that this maker of devices for treating obstructive sleep apnea would post a loss of $0.63 per share when it actually produced a loss of $0.34, delivering a su ...

MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the FDA approval of the Inspire V therapy system which includes the next generation neurostimulator and the associated Bluetooth® patient remote and physician programmer. "We are thrilled to announce the FDA approval of our ...

MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the FDA approval of the Inspire V therapy system which includes the next generation neurostimulator and the associated Bluetooth® patient remote and physician programmer. "We are thrilled to announce the FDA approval of our ...

Core Insights - Inspire Medical Systems reported preliminary results indicating second-quarter and full-year revenue exceeding analysts' estimates [2] - The company expects second-quarter sales to be 30% higher compared to the same period last year [2] - Inspire anticipates full-year revenue growth of 26% to 28% for 2024, with projected revenue between $788 million and $798 million [2] Financial Performance - The expected second-quarter revenue is $195.9 million, reflecting a 30% increase year-over-year [2] - The previous revenue outlook for the full year was $775 million to $785 million, which has been revised upward [2] - Inspire's shares rose approximately 4% following the announcement, although they remain down about 35% year-to-date [2] Management Commentary - CEO Tim Herbert expressed increased confidence in strong continued revenue growth for the second half of the year [2]

Preliminary, Unaudited Second Quarter Revenue Updated Full Year 2024 Revenue Guidance "We are so proud of our team's strong execution and revenue performance in the second quarter, which showed sequential revenue growth acceleration in the U.S.," said Tim Herbert, Chairman and CEO of Inspire. "With the strong momentum we are seeing in our business, we have increased confidence regarding strong continued revenue growth in the second half of 2024. As a result, we are increasing our revenue guidance to $788 mi ...